1. Correlation between lower extremity arterial disease and skeletal muscle mass in patients with type 2 diabetes mellitus
- Author
-
Yinghui Zhang, Dongqing Jiang, Yihong Ni, Fengjie Zheng, Xianghua Zhuang, Lemeng Ren, Shihong Chen, and Xiaobao Li
- Subjects
medicine.medical_specialty ,Medicine (General) ,endocrine system diseases ,Arterial disease ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Biochemistry ,Body fat percentage ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Waist–hip ratio ,R5-920 ,Internal medicine ,medicine ,Macrovascular disease ,business.industry ,Biochemistry (medical) ,Type 2 Diabetes Mellitus ,nutritional and metabolic diseases ,Cell Biology ,General Medicine ,Skeletal muscle mass ,medicine.disease ,chemistry ,Concomitant ,Cardiology ,Uric acid ,business ,Corrigendum - Abstract
Objectives To evaluate skeletal muscle mass in patients with both type 2 diabetes mellitus (T2DM) and concomitant lower extremity arterial disease (LEAD) and determine the contribution of skeletal muscle mass to macrovascular diseases. Methods In total, 112 patients with T2DM were divided into the T2DM and T2DM + LEAD groups. Hepatic function, renal function, uric acid, blood glucose, and glycated hemoglobin (HbA1C) were measured. Dual-energy X-ray absorptiometry was used to measure visceral fat area and skeletal muscle mass index (SMI). Results Waist-to-hip ratio, uric acid, and body fat percentage were significantly higher in the T2DM+LEAD group than in the T2DM group; SMI was significantly lower in the T2DM+LEAD group than in the T2DM group. There were no significant differences in albumin, creatinine, fasting blood glucose, HbA1C, or blood lipids. Uric acid, SMI, and body fat percentage were significantly positively correlated with T2DM and concomitant LEAD. Logistic regression analyses suggested that SMI is an independent risk factor for LEAD in T2DM (odds ratio = 1.517; 95% confidence interval: 1.082–2.126). Conclusions Skeletal muscle mass is lower in patients with T2DM and concomitant LEAD than in patients with T2DM who do not exhibit LEAD. SMI is an important risk factor for LEAD.
- Published
- 2020